Luigi Mangione pleads guilty in federal court to stalking health-insurance CEO. That could affect the state's case.
By Jaimy Lee
A New York state murder trial is expected to begin next month
Luigi Mangione attends a pretrial appearance on Tuesday at Manhattan Criminal Court in New York City. Mangione is accused of fatally shooting UnitedHealthcare CEO Brian Thompson and is facing state murder charges.
Luigi Mangione, who is accused of killing a UnitedHealthcare executive, pled guilty to federal stalking charges ahead of a high-profile state murder trial in New York set to begin next month.
Mangione entered his plea Friday in the U.S. District Court for the Southern District of New York, where he is facing two stalking charges resulting in the death of the CEO of UnitedHealth Group's (UNH) health-insurance unit UnitedHealthcare, Brian Thompson, in December 2024. Mangione is also facing a murder charge in New York state.
"On the morning of Dec. 4, 2024, I shot Mr. Thompson in Manhattan," Mangione said Friday during the court hearing, according to a Wall Street Journal report.
He told the judge that he had contacted the company before its annual investor conference, posing as an investor at a firm with $50 million in assets, the Journal reported.
The shooting caused widespread concern about corporate executive safety, including at other health-insurance companies. A month after the shooting, none of the executive teams at other health-insurance companies attended a popular healthcare investor conference in San Francisco. The shooting also led to a surge in public criticism about the role of health-insurance companies in limiting or denying medical care.
Mangione is set to be sentenced in December.
The New York state trial is expected to begin next month. Mangione's lawyer has asked the state to dismiss its charges, citing double-jeopardy protections.
-Jaimy Lee
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
08-15-26 0951ET
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Dividend Stocks
12 Best Blue-Chip Stocks to Buy for the Long Term
United States